CNS HIV ANTIRETROVIRAL EFFECTS RESEARCH (CHARTER)

CNS HIV 抗逆转录病毒作用研究（章程）

• 批准号: 7719177
• 负责人: BENJAMIN B. GELMAN
• 金额: $ 23.41万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7719177
• 关键词: AIDS neuropathy; Affect; Anti-Retroviral Agents; Biopsy; Blood; Body fat; Collection; Complication; Computer Retrieval of Information on Scientific Projects Database; Data; Dementia; Evaluation; Funding; Grant; HIV; Impairment; Institution; Laboratories; Learning; Magnetic Resonance Imaging; Medical; Metabolic; Nature; Neural Conduction; Neurologic Examination; Participant; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Prevention; Recording of previous events; Research; Research Personnel; Resources; Sensory; Site; Skin; Source; Spinal Puncture; Spinal Tap; Testing; United States National Institutes of Health; design; interest; nervous system disorder; neuropsychological; programs; psychologic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The aim of the CHARTER Program is to examine the evolving nature of neuroAIDS, particularly with modern HIV medication use. The study was designed as a 5-year program (2002-2007) with a 3-year extension (2007-2010). This three year period was seen as an opportunity to gather additional data. The Investigators are interested in learning more about HIV-associated neurological disease and will collect detailed medical, laboratory, psychological and psychiatric histories and evaluations over the next 3 years on approximately 300 people, every six months at the 6 sites. This information will help them understand if and how anti-retroviral medications (HAART) affect the complication or prevention of neurological disease and impairment (such as dementia or peripheral neuropathy) in those infected with HIV. Researchers are also interested in the effect HAART has on the metabolic changes that often occur, i.e., loss of or redistribution of body fat. A secondary concern is how HAART and psychiatric medications interact. Study participants will be asked to undergo testing every 6 months. Basic testing will include neurological examination, neuropsychological evaluation, psychiatric history, blood collection, and a lumbar puncture. Additional testing may include nerve conduction studies, quantitative sensory testing, MRI, and or skin biopsy.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 CHARTER 计划的目的是研究神经艾滋病的演变性质，特别是现代艾滋病毒药物的使用。 该研究设计为一个为期 5 年的计划（2002-2007 年），并可延长 3 年（2007-2010 年）。这三年被视为收集更多数据的机会。研究人员有兴趣更多地了解与 HIV 相关的神经系统疾病，并将在未来 3 年中每六个月在 6 个地点收集大约 300 人的详细医疗、实验室、心理和精神病史和评估。这些信息将帮助他们了解抗逆转录病毒药物 (HAART) 是否以及如何影响 HIV 感染者的神经系统疾病和损伤（如痴呆或周围神经病变）的并发症或预防。 研究人员还对 HAART 对经常发生的代谢变化（即体内脂肪的减少或重新分配）的影响感兴趣。 第二个问题是 HAART 和精神科药物如何相互作用。研究参与者将被要求每 6 个月接受一次测试。 基本测试包括神经系统检查、神经心理学评估、精神病史、血液采集和腰椎穿刺。 其他测试可能包括神经传导研究、定量感觉测试、MRI 和/或皮肤活检。